Inflammatory Myofibroblastic Tumor of the Hilar Bile Duct: A Case Report and Literature Review

Sheng-qiang Gao, Yong-jin Bao and Jian-sheng Luo*

Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China

Background: Inflammatory myofibroblastic tumor (IMT) is a very rare tumor and occurs seldom in the biliary tract. IMT can occur in any part of the body and in people of any age; however, it most commonly occurs in children or adolescents. Its etiology and pathogenesis are currently unknown. The clinical manifestations of a hilar inflammatory myofibroblastic tumor are atypical, and the imaging examination is nonspecific. The diagnosis is mainly based on histopathology and immunohistochemistry findings, and surgical resection is the preferred treatment method.

Case Description: Herein, we report a rare case of hilar bile duct IMT and review the related literature. Our patient was a 54-year-old woman presenting with a 1-day history of upper abdominal pain as the main clinical symptom. She was misdiagnosed as having cholangiocarcinoma before the surgery. She underwent surgery and was ultimately diagnosed with IMT based on histopathology and immunohistochemistry findings. On 1-year follow-up, no tumor recurrence or related complications were noted.

Conclusions: We hope this case report helps clinicians gain a deeper understanding of biliary IMT of the hilum.

Keywords: inflammatory, myofibroblastic, tumor, hilar bile duct, case report

INTRODUCTION

Inflammatory myofibroblastic tumor (IMT) is an exceedingly rare mesenchymal tumor. It is an assembly of differentiated myofibroblastic spindle cells, which commonly presents with the infiltration of large amounts of plasma cells and lymphocytes (1). The lung was the first identified onset site of IMT by Bahadori and Liebow in 1973 (2); thereafter, the mesentery, mediastinum, liver, peritoneum, skin, breast, nerves, bones, and the central nervous system have been reported as onset sites as well (3, 4). The biliary tract is seldom involved, and there are very few reports on the IMT of the biliary tract (5). At present, the pathogenesis of IMT remains elusive. Besides, it is difficult to diagnose given the atypical laboratory and imaging findings, particularly the IMT of the hilum, which is extremely rare. In this context, there is a high risk of misdiagnosis as a malignant lesion. At present, the diagnosis of IMT is mainly based on the histopathology and immunohistochemistry findings, and surgical resection remains the primary treatment. Herein, we report a case of biliary IMT of the hilum and review the literature.
CASE REPORT

A 54-year-old woman visited our hospital on January 30, 2021 with a 1-day history of pain in the middle upper abdomen. On the day before the admission, she experienced pain in the middle upper abdomen with no obvious precipitating factors. The pain was paroxysmal but not radiating and accompanied yellowing of the skin and eyes. There was no manifestation of fever, vomiting, or diarrhea. When she visited our emergency department, abdominal enhanced CT was performed, wherein dilation of the upper common bile duct (with soft tissue shadows) and intrahepatic bile duct was observed, which led us to suspect a tumor. The patient was then admitted due to an initial diagnosis of a bile duct tumor. Physical examination revealed mild yellowing of the skin and sclera, and no tenderness or palpable mass was noted in the abdomen. The patient reported a previous history of diabetes, which was being managed with oral metformin. She denied having any past medical history of hypertension, heart disease, hepatitis B, tuberculosis, renal disease, pulmonary disease, and smoking and alcohol abuse. She underwent myomectomy three years ago. Routine blood test findings were normal. Blood biochemical profile revealed the following: total bilirubin = 96.1 µmol/L (normal range: 2–25 µmol/L), direct bilirubin = 54.3 µmol/L (normal range: 0–10 µmol/L), indirect bilirubin = 41.8 µmol/L (normal range: 0–10 µmol/L) and alanine aminotransferase (ALT) 616.4 IU/L (normal range: 9–50 IU/L). Tumor markers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and alpha-fetoprotein (AFP), were normal. Immunoglobulin G4 (IgG4) was normal as well.

On enhanced MRI of the upper abdomen, the bile duct of the hilum was involved with intrahepatic bile duct dilation, suggesting cholangiocarcinoma. Figure 1 presents the T1 image and Figure 2 presents the T2 image, and the location of the swelling is indicated with a red arrow. In addition, the presence of multiple hepatic masses was noted as well. A small nodule was observed in the right lung. The hepatic mass was considered to possibly have metastatic potential, and its resection was planned. Multiple cysts were observed in both kidneys. Chest CT showed an atelectatic right lung and a ground-glass nodule in the right lower lobe. An initial diagnosis of cholangiocarcinoma of the hilum was made. The patient was then treated with laparoscopic resection of the bile duct tumor under general anesthesia + bile duct plastic repair + Roux-en-Y biliary-enteric anastomosis + resection of hepatic hemangioma. Cholestasis, evident gallbladder swelling, and common bile duct dilation (∼2 cm) were identified during the procedure. In the meantime, two hyperechogenic small nodules (∼0.8 cm) were identified in the liver VIII segment using an ultrasonic probe; these were partially resected using an ultrasonic knife and then pathologically diagnosed as hepatic hemangioma. The bile duct tumor of the hilum was resected along with the gallbladder. The duodenum of the common bile duct was detached, and the lower bile duct was ligated. The hepatoduodenal ligament was dissected. The bile duct above the bifurcation of the right and left hepatic ducts

![FIGURE 1](https://example.com/figure1.png)

**FIGURE 1** | Enhanced MRI image of the patient: soft tissue shadow (indicated by arrow) measuring approximately 1.5 × 1.8 cm can be seen in the hepatic hilum. T1 image: the tumor appears as a slightly low-signal-intensity mass.
and the two bile ducts of the caudate liver lobes were detached. The separated bile ducts were cut. The tumor was located in the hilum and presented with yellow fat with an intact envelope (Figure 3). Rapid intraoperative pathology indicated negative bile duct margins, suggesting IMT. A Roux-en-Y biliary-enteric anastomosis was performed instead of right hemihepatectomy. First, the four separated bile duct openings were intermittently stitched together with 5-0 prolene sutures (Figure 4). Two silicone tubes were placed into the two bile duct openings of the caudate liver lobe, which supported smooth drainage and prevented the closure of the bile ducts. Bile duct plastic repair was performed laparoscopically as it offers low risk of biliary leakage after sutures; this was followed by the Roux-en-Y biliary-enteric anastomosis. Postoperative pathology identified the hepatic nodule as a hemangioma and revealed that the hilar mass presented with storiform hyperplasia of fibroblasts with interstitial collagen and infiltrating plasma cells and lymphocytes, which are consistent with the presentation of IMT (Figure 5). Besides, margin-negative tests were obtained in all bile ducts. Our surgery achieved R0 resection. Immunohistochemistry revealed smooth muscle actin (weak +), CD34 (−), CD117 (−), Des (−), ki67 (+) <5%, CD21 (−), and CD23 (−). Figure 6 shows positive staining for smooth muscle actin, and Figure 7 shows positive staining for Ki67 in tumor cells. Biliary IMT of the hilum was finally diagnosed. The patient was uneventful after the surgery and had no biliary leakage, abdominal hemorrhage, or infection. The patient was discharged on day 7 postoperatively. No tumor recurrence or metastasis was noted at 1-year follow-up. The timeline of the patient’s symptoms, treatment, and prognosis in our case is shown in Figure 8.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and were in compliance with the tenets of the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from the patient for performing the procedures and publishing the findings as images and text.

DISCUSSION

IMTs typically comprise myofibroblastic and fibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and/or eosinophils. Previously, IMT has been referred to as plasma cell granuloma, inflammatory pseudotumor, inflammatory myofibrohistiocytic proliferation, and inflammatory fibrosarcoma. According to the WHO Classification of Tumours: Soft Tissue and Bone Tumours, 2020, IMT was defined as a unique and rare metastatic tumor. It is generally considered benign even though it shares multiple similar characteristics with various invasive malignancies in terms of clinical and radiological manifestations. However, different biological behaviors may be presented by these tumors (6). IMT is defined as an intermediate-grade tumor by WHO and has a propensity for regional recurrence but low incidence of metastasis (7); its incidence does not significantly differ between men and women.
At present, the pathogenesis of IMT is still unclear; however, there are four possible factors that may lead to IMT. (1) Excessive inflammatory reactions caused by trauma or surgical operations and (2) infections caused by *Escherichia coli*, *Staphylococcus* spp., and Gram-positive bacteria have been reported to be associated with IMT development. (3) Some autoimmune diseases, such as primary biliary cirrhosis, thyroiditis, autoimmune pancreatitis, Crohn's disease, Sjögren's syndrome, idiopathic thrombocytopenic purpura, and gout, among others can also cause IMT. In fact, IgG4 has been reported to be significantly elevated in some patients with IMT, and infiltration of IgG4-positive plasm cells in the focus, majorly including cytokeratin, has been reported; however, notably, our case showed no elevation of IgG4. (4) aberrant ALK (anaplastic lymphoma receptor tyrosine kinase) gene expression has been recently reported to be associated with IMT in some patients. Aberrant NPM-ALK fusion proteins were first reported in anaplastic large cell lymphoma by Morris et al. Aberrant ALK expression has also been reported in IMT, and currently identified ALK fusion genes in IMT include TPM3, TPM4, CLTC, and CARS. It has been established that aberrant ALK gene expression can cause ALK protein abnormality, thus resulting in abnormal proliferation of myofibroblasts and the subsequent advancement of tumorigenesis.

The clinical presentation of IMT is generally atypical and mainly associated with the tumor site. In cases that involve the bile duct, the clinical presentation commonly involves painless obstructive jaundice, abdominal pain, weight loss, and fever. The case reported herein presented with jaundice and abdominal pain, which is considered to have resulted from bile duct obstruction because of the tumor. Moreover, the common laboratory findings include increased white blood cell count, elevated liver enzymes, and abnormal serum bile acid levels.
FIGURE 5 | Tumor pathological HE staining pictures: fibroblasts with striae-like proliferation with interstitial collagenization and infiltration of lymphocytes and plasma cells (magnification, ×40).

FIGURE 6 | A photomicrograph of immunohistochemistry staining of the lesion. Tumor cells were positive for smooth muscle actin. Smooth muscle of blood vessels acted as an internal positive control. (magnification, ×100).
cell count and C-reactive proteins levels, marginally elevated liver enzymes, normal CEA and serum AFP levels, and marginally increased CA19-9 levels in some patients (5). Our case did not show elevated CA19-9 levels. The increase in CA19-9 levels is not specific to bile duct carcinoma and can occur even in benign cases with liver and gall diseases.

The imaging findings of IMT are generally atypical. On computed tomography (CT), it generally appears as soft tissue

FIGURE 7 | A photomicrograph of immunohistochemistry staining of the lesion. The expression of Ki67 in tumor cells is about 5%. (magnification, ×100).

FIGURE 8 | Timeline of symptoms, treatment, and prognosis in our case.

The patient was first admitted to our hospital with intermittent pain in his middle upper abdomen.

The patient was then treated with laparoscopic resection of the bile duct tumor under general anesthesia + bile duct plastic repair + Roux-en-Y biliary-enteric anastomosis + resection of hepatic hemangioma.

2021/01/30
On enhanced MRI of the upper abdomen, the bile duct of the hilum was involved with intrahepatic bile duct dilation, suggesting cholangiocarcinoma.

2021/02/02
2021/02/05
The patient was discharged on day 7 postoperatively. No tumor recurrence or metastasis was noted at 1-year follow-up.

2021/02/12
In inflammatory myofibroblastic tumor of the duct, the lesions are commonly presented as soft tissue masses with unclear boundaries and irregular morphology. The case reported herein had a slightly hypoechogenic mass on T1WI and a slightly hyperechogenic mass on T2WI in MRI scans.

The definitive diagnosis of IMT relies on histopathology and immunohistochemistry findings. Some IMT tumors have clear boundaries and pseudocapsules. In cases of recurrence, the boundaries may become irregular, and the tumors can invade the surrounding muscles or bone tissues. Recently, ALK has been identified as a favorable diagnostic biomarker for IMT, with approximately 50%–70% of IMT cases showing ALK positivity. In addition, high IgG4 expression can also be referenced during the diagnosis of IMT. Immunohistochemical studies on T-cell and B-cell subsets may be conducive to differentiating between IMT and lymphoma.

It is important to distinguish biliary IMT from cholangiocarcinoma. In cases with cholangiocarcinoma, manifestations on a plain CT scan image may include low-density or slightly low-density shadows and iso-density shadows. On enhanced CT scans, arterial phase enhancement of varying degrees is noted, and mild or moderate venous phase enhancement which is inhomogeneous and network-like is present. In addition, manifestations on a plain MRI scan image include T1 signals that are slightly longer relative to the surrounding tissues, T2 signals that are slightly longer or the same length relative to the surrounding tissues, and some T1 signals that are shorter relative to the surrounding tissues in the dilated bile duct. The case reported here was preoperatively misdiagnosed as a cholangiocarcinoma of the hilum and was later confirmed as biliary IMT by postoperative histopathology and immunohistochemistry.

Surgical resection is currently the preferred treatment for biliary IMT as this type of a solid tumor is commonly misdiagnosed as a malignancy under imaging techniques. For patients with contradictions for surgery, other treatments, such as large-dose steroid hormones, nonsteroidal anti-inflammatory drugs, chemotherapy, and radiotherapy, are recommended. However, the efficacy of chemotherapeutics remains debatable and needs to be established with further large-scale case studies. A case of IMT was reportedly treated with oral non-steroidal anti-inflammatory drugs or steroids. In our patient, the bile duct of the hilum was obstructed by the tumor, and the upper bile duct was dilated, which warranted prompt surgical treatment.

For the past few years, ALK-I has been reported to exhibit high expression in IMT, with a positivity rate of as high as 89% in immunohistochemistry. ALK is also associated with the activation of some other tyrosine kinases because of the regional tumor relapse and metastasis. Crizotinib is a tyrosine kinase inhibitor of the ALK receptor; it can suppress the activity of ALK fusion proteins by competing against adenosine triphosphate for binding with the ALK receptor, thereby blocking pathological signaling transmission and subsequently suppressing the spread of tumor cells. Crizotinib is an FDA-approved therapeutic drug for ALK-positive non-small cell lung cancer. Moreover, clinical trials have also upheld its effectiveness in treating ALK-positive anaplastic large cell lymphoma and neuroblastoma. However, considering the limited therapeutic options, particularly for patients with ALK-negative tumors, Recine et al. reported the role of microenvironmentally targeted agents, such as trabectedin, in the treatment of recalcitrant soft tissue sarcomas. The unique antitumor activity of trabectedin comprises not only its cytotoxic activity but also its ability to modulate the tumor microenvironment. There are some recent reports on cases of ALK-negative IMT. Mai et al. reported a case of ALK-negative pulmonary IMT wherein the patient achieved sustained remission after treatment with crizotinib (250 mg, bid). He et al. reported a case of a 68-year-old woman with intrapancreatic IMT and invasion of the spleen and diaphragm; the woman was found to be ALK-negative by next-generation sequencing but showed dual amplification of CDK4 and MDM2. Shah et al. reported a case of ALK-negative IMT after 12 years of treatment for synovial sarcoma in both lower extremities, and the patient had a good prognosis without signs of recurrence at postoperative follow-up.

In addition to ALK, other gene rearrangements need to be studied. Besides conventional assays, such as immunohistochemical testing and fluorescence in situ hybridization, more extensive molecular assays, such as next-generation sequencing (NGS), may also be required to explore genetic signatures more comprehensively, which could be an important clinical resource. IMT is generally benign and classified as an intermediate-grade tumor characterized by a potential for recurrence and a low incidence of metastasis. Regional recurrence is common, but it is rare to see a local infiltrating or malignant lesion with distant metastasis. IMT is more invasive when it initiates in the abdomen or retroperitoneum than other sites and presents with a relatively high risk of multiple recurrences and distant metastasis. A study in 2007 revealed that patients with ALK-negative IMT were prone to metastasis. In the present case, no evidence of tumor metastasis or recurrence was observed at the 1-year follow-up.
However, this study has some limitations. First, our patient was considered to have bile duct cancer preoperatively, and the liver mass lesion was not clear. At that time, PET-CT should have been considered to more accurately determine the nature of the hilar mass and liver mass and give us a point of reference. Second, the patient did not undergo genetic testing after the operation, and thus, we do not know whether the patient had positive expression of related ALK gene. However, if the patient is identified as having recurrence or metastasis of the disease during the regular postoperative follow-ups, we will recommend the patient to undergo genetic testing.

CONCLUSIONS

To conclude, biliary IMT of the hilum is exceedingly rare and shows atypical clinical presentation and laboratory and imaging findings. Postoperative pathology is the main approach for a definitive diagnosis. Surgery is the preferred and primary treatment of this disease, and most patients recover well postoperatively with a low incidence of recurrence.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

REFERENCES

1. Gómez-Román JJ, Ocejo-Vinyals G, Sánchez-Velasco P, Nieto EH, Leyva-Cobián F, Val-Bernal JF. Presence of human herpesvirus-8 DNA sequences and overexpression of human IL-6 and cyclin D1 in inflammatory myofibroblastic tumor (inflammatory pseudotumor). Lab Invest. (2000) 80:1121–6. doi: 10.1038/labinvest.3780118

2. Bahadori M, Liebow AA. Plasma cell granulomas of the lung. Cancer. (1973) 31:191–208. doi: 10.1002/1097-0142(197301)31:1<191::AID-CNCR2820310127>3.0.CO;2-d

3. Vasilidiás K, Fortounis K, Papavasiliou C, Kokarhidas A, Al Nimer A, Fachiridis D, et al. Md common bile duct inflammatory pseudotumor mimicking cholangiocarcinoma. A case report and literature review. Int J Surg Case Rep. (2014) 5:12–5. doi: 10.1016/j.jscr.2013.10.017

4. Verma R, Saha A, Saha K. Inflammatory myofibroblastic tumor of the mid common bile duct masquerading as cholangiocarcinoma. J Gastrointest Cancer. (2019) 50:613–6. doi: 10.1007/s12029-018-0074-7

5. Elpek GÖ. Inflammatory myofibroblastic tumor of the liver: a diagnostic challenge. J Clin Transl Hepatol. (2014) 2:53–7. doi: 10.14218/jcth.2013.00023

6. Biniraj KR, Janardhanan M. Inflammatory myofibroblastic tumor of maxilla showing sarcomatous change in an edentulous site with a history of tooth extraction following periodontitis: a case report with discussion. J Indian Soc Periodontol. (2014) 18:375–8. doi: 10.4103/0977-124x.134582

7. Berumen J, McCarty P, Mo J, Newton K, Fairbanks T, Mkeel K, et al. Combined liver transplant and pancræaticoduodenectomy for inflammatory hilar myofibroblastic tumor: case report and review of the literature. Pediatr Transplant. (2017) 21:339–41. doi: 10.1111/pet.12846

8. Narla LD, Newman B, Spottswood SS, Narla S, Kolli R. Inflammatory pseudotumor. Radiographics. (2003) 23:719–29. doi: 10.1148/radi.233025073

9. Faraj W, Ajouz H, Mukherji D, Kealy G, Shamseddine A, Khalife M. Inflammatory pseudo-tumor of the liver: a rare pathological entity. World J Surg Oncol. (2011) 9:5. doi: 10.1186/1477-7819-9-5

10. Aguirre-Garcia J. Inflammatory pseudotumor of the liver. Ann Hepatol. (2004) 3:34

11. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. (1994) 263:1281–4. doi: 10.1126/science.8122112

12. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. (2000) 157:377–84. doi: 10.1016/s0002-9440(10)64550-6

13. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. (2007) 31:509–20. doi: 10.1097/01.pas.0000213393.57322.c7

14. Kim A, Lee MW, Nguyen GK. Inflammatory myofibroblastic tumour of the pancreas. Can J Surg. (2008) 51:E23–4.

15. Ong HS, Li T, Zhang CP, Li J, Wang LZ, Li RR, et al. Head and neck inflammatory myofibroblastic tumor (IMT): survival and prognostic features. Oral Oncol. (2012) 48:141–8. doi: 10.1016/j.oraloncology.2011.09.004

16. Choquale A, Bal A, Das A, Agarwal R, Singh N, Rao KL. A comparative study of inflammatory myofibroblastic tumors and tumefactive IgG4-related inflammatory lesions: the relevance of IgG4 plasma cells. Appl Immunohistochem Mol Morphol. (2016) 24:721–8. doi: 10.1097/pai.0000000000000252

17. Saab ST, Hornick JL, Fletcher CD, Olson SJ, Coffin CM. IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? Mod Pathol. (2011) 24:606–12. doi: 10.1038/modpathol.2010.226

18. Ding D, Bu X, Tian F. Inflammatory myofibroblastic tumor in the head of the pancreas with anorexia and vomiting in a 69-year-old man: a case report. Oncol Lett. (2016) 12:1546–50. doi: 10.3892/ol.2016.4787

19. Jacob SV, Reith JD, Kojima AY, Williams WD, Liu C, Vila Duckworth L. An unusual case of systemic inflammatory myofibroblastic tumor with successful

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The authors are accountable for all aspects of the work and ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from the patient. The study was approved by the Ethics Committee of the Affiliated Jinhua Hospital, Zhejiang University School of Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

S-qG: Conceptualization, Methodology, Funding acquisition, Writing- Original draft preparation. Y-jB: Investigation, Data Curation. J-sL: Writing- Reviewing and Editing. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Jinhua Science and Technology Research Project (No.2021-3-056).
treatment with alk-inhibitor. *Case Rep Pathol.* (2014) 2014:470340. doi: 10.1155/2014/470340

20. Tsou YK, Lin CJ, Liu NJ, Lin CC, Lin CH, Lin SM. Inflammatory pseudotumor of the liver: report of eight cases, including three unusual cases, and a literature review. *J Gastroenterol Hepatol.* (2007) 22:2143–7. doi: 10.1111/j.1440-1746.2006.04514.x

21. Pecoraro Y, Diso D, Anile M, Russo E, Patella M, Venuta F. Primary inflammatory myofibroblastic tumor of the trachea. *Respirol Case Rep.* (2014) 2:147–9. doi: 10.1002/rcr2.81

22. Hallberg B, Palmer RH. Crizotinib – latest champion in the cancer wars? *N Engl J Med.* (2010) 363:1760–2. doi: 10.1056/NEJMe1010404

23. Croegaert K, Kolesar JM. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm.* (2015) 72:1456–62. doi: 10.2146/ajhp140836

24. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, et al. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther.* (2017) 10:1155–64. doi: 10.2147/ott.S127955

25. Mai S, Xiong G, Diao D, Wang W, Zhou Y, Cai R. Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. *Lung Cancer.* (2019) 128:101–4. doi: 10.1016/j.lungcan.2018.12.016

26. He J, Zhao X, Huang C, Zhou X, You Y, Zhang L, et al. Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm. *Cancer Biol Ther.* (2018) 19:967–72. doi: 10.1080/15384047.2018.1480290

27. Shah A, Poy E, Achouru JU, Bai JDK, Khan F. Inflammatory myofibroblastic tumor 12 years after treatment for synovial sarcoma: a case report. *Orthop Res Rev.* (2021) 13:163–9. doi: 10.2147/orr.S333124

28. Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. *Am J Surg Pathol.* (2015) 39:957–67. doi: 10.1097/pas.000000000000404

29. Debonis SA, Bongiovanni A, Pieri F, Fausti V, De Vita A, Riva N, et al. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: a case report and literature review of molecular alterations. *Medicine (Baltimore).* (2021) 100:e25972. doi: 10.1097/md.0000000000025972

30. Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, et al. Next-generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC sarcoma working group. *Front Oncol.* (2020) 10:489. doi: 10.3389/fonc.2020.00489

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gao, Bao and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.